Eli Lilly & Co. (LLY)
1149.36
-10.24
(-0.88%)
USD |
NYSE |
Sep 04, 16:00
1146.66
-2.70
(-0.23%)
Pre-Market: 20:00
Eli Lilly Research and Development Expense (Quarterly) : 3.819B for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.819B |
| March 31, 2026 | 3.51B |
| December 31, 2025 | 3.802B |
| September 30, 2025 | 3.466B |
| June 30, 2025 | 3.336B |
| March 31, 2025 | 2.734B |
| December 31, 2024 | 3.022B |
| September 30, 2024 | 2.734B |
| June 30, 2024 | 2.711B |
| March 31, 2024 | 2.523B |
| December 31, 2023 | 2.563B |
| September 30, 2023 | 2.409B |
| June 30, 2023 | 2.356B |
| March 31, 2023 | 1.985B |
| December 31, 2022 | 1.996B |
| September 30, 2022 | 1.803B |
| June 30, 2022 | 1.782B |
| March 31, 2022 | 1.610B |
| December 31, 2021 | 1.959B |
| September 30, 2021 | 1.709B |
| June 30, 2021 | 1.673B |
| March 31, 2021 | 1.685B |
| December 31, 2020 | 1.838B |
| September 30, 2020 | 1.465B |
| June 30, 2020 | 1.390B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.392B |
| December 31, 2019 | 1.581B |
| September 30, 2019 | 1.381B |
| June 30, 2019 | 1.402B |
| March 31, 2019 | 1.230B |
| December 31, 2018 | 1.392B |
| September 30, 2018 | 1.281B |
| June 30, 2018 | 1.271B |
| March 31, 2018 | 1.108B |
| December 31, 2017 | 1.473B |
| September 30, 2017 | 1.319B |
| June 30, 2017 | 1.251B |
| March 31, 2017 | 1.238B |
| December 31, 2016 | 1.451B |
| September 30, 2016 | 1.236B |
| June 30, 2016 | 1.336B |
| March 31, 2016 | 1.221B |
| December 31, 2015 | 1.444B |
| September 30, 2015 | 1.143B |
| June 30, 2015 | 1.170B |
| March 31, 2015 | 1.039B |
| December 31, 2014 | 1.186B |
| September 30, 2014 | 1.243B |
| June 30, 2014 | 1.195B |
| March 31, 2014 | 1.109B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Johnson & Johnson | 3.603B |
| Merck & Co., Inc. | 9.229B |
| Pfizer Inc. | 2.746B |
| Bristol Myers Squibb Co. | 2.316B |
| Atai Beckley, Inc. | 28.07M |